$HRTX
Heron Therapeutics Inc

2014 Q4 Form 10-K Financial Statement

#000119312516469890 Filed on February 19, 2016

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.590M $4.220M $4.510M
YoY Change 2.01% -34.57% -3.63%
% of Gross Profit
Research & Development $14.20M $14.73M $14.28M
YoY Change 70.0% 136.83% 35.6%
% of Gross Profit
Depreciation & Amortization $190.0K $150.0K $130.0K
YoY Change 111.11% 66.67% 62.5%
% of Gross Profit
Operating Expenses $14.20M $18.95M $18.79M
YoY Change 2.64% 49.71% 23.54%
Operating Profit -$18.95M -$18.79M
YoY Change
Interest Expense $227.0K $224.0K $220.0K
YoY Change -208.1% -206.67% -210.0%
% of Operating Profit
Other Income/Expense, Net -$905.0K -$17.00K
YoY Change
Pretax Income -$20.62M -$19.19M -$19.01M
YoY Change 46.87% 49.11% 23.36%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.62M -$19.19M -$19.01M
YoY Change 46.89% 49.14% 23.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$705.2K -$661.7K -$783.3K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $72.70M $86.20M $105.0M
YoY Change 0.55% 281.42% 201.72%
Cash & Equivalents $72.68M $86.21M $105.0M
Short-Term Investments
Other Short-Term Assets $1.100M $3.000M $500.0K
YoY Change 83.33% 275.0% 25.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $73.73M $89.20M $105.5M
YoY Change 1.14% 281.2% 199.72%
LONG-TERM ASSETS
Property, Plant & Equipment $2.820M $2.900M $3.000M
YoY Change -2.76% 0.0% 11.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $130.0K $100.0K $100.0K
YoY Change 30.0% -50.0% 0.0%
Total Long-Term Assets $2.950M $3.100M $3.100M
YoY Change -1.67% 3.33% 6.9%
TOTAL ASSETS
Total Short-Term Assets $73.73M $89.20M $105.5M
Total Long-Term Assets $2.950M $3.100M $3.100M
Total Assets $76.68M $92.30M $108.6M
YoY Change 1.03% 249.62% 185.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.549M $1.500M $1.800M
YoY Change 96.08% -34.78% -66.67%
Accrued Expenses $9.500M $8.300M $7.700M
YoY Change 102.13% 245.83% 120.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.600M $1.500M $1.300M
YoY Change 60.0% 66.67% 62.5%
Total Short-Term Liabilities $13.62M $11.30M $10.80M
YoY Change 94.57% 105.45% 12.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $13.62M $11.30M $10.80M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $13.60M $11.30M $10.80M
YoY Change 94.29% 105.45% 12.5%
SHAREHOLDERS EQUITY
Retained Earnings -$315.2M
YoY Change
Common Stock $292.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $63.06M $81.00M $97.80M
YoY Change
Total Liabilities & Shareholders Equity $76.68M $92.30M $108.6M
YoY Change 1.03% 249.62% 185.04%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2014 Q2
OPERATING ACTIVITIES
Net Income -$20.62M -$19.19M -$19.01M
YoY Change 46.89% 49.14% 23.37%
Depreciation, Depletion And Amortization $190.0K $150.0K $130.0K
YoY Change 111.11% 66.67% 62.5%
Cash From Operating Activities -$12.85M -$19.24M -$12.48M
YoY Change 33.58% 55.66% 15.34%
INVESTING ACTIVITIES
Capital Expenditures -$1.020M -$80.00K -$280.0K
YoY Change 500.0% -91.84% 180.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.020M -$80.00K -$280.0K
YoY Change 500.0% -91.84% 180.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 340.0K 520.0K 60.29M
YoY Change -99.43% -51.85% 100383.33%
NET CHANGE
Cash From Operating Activities -12.85M -19.24M -12.48M
Cash From Investing Activities -1.020M -80.00K -280.0K
Cash From Financing Activities 340.0K 520.0K 60.29M
Net Change In Cash -13.53M -18.80M 47.53M
YoY Change -127.23% 53.34% -537.66%
FREE CASH FLOW
Cash From Operating Activities -$12.85M -$19.24M -$12.48M
Capital Expenditures -$1.020M -$80.00K -$280.0K
Free Cash Flow -$11.83M -$19.16M -$12.20M
YoY Change 25.19% 68.37% 13.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
5231000
CY2014Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
3811000
CY2015 hrtx Amortization Of Shortterm Investment Premium
AmortizationOfShorttermInvestmentPremium
89000
CY2014 hrtx Amortization Of Shortterm Investment Premium
AmortizationOfShorttermInvestmentPremium
CY2013 hrtx Amortization Of Shortterm Investment Premium
AmortizationOfShorttermInvestmentPremium
CY2011Q3 hrtx Common Shares Registered For Resale In Connection With Convertible Notes
CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes
3500000
CY2015Q4 hrtx Common Stock Underlying Convertible Notes Outstanding
CommonStockUnderlyingConvertibleNotesOutstanding
7086560
CY2011Q2 hrtx Convertible Debt Issuable In Connection With Private Placement1
ConvertibleDebtIssuableInConnectionWithPrivatePlacement1
4500000
CY2015Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
2222000
CY2014Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
1598000
CY2015 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
7950
CY2014 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
7800
CY2013 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
7650
CY2015Q4 hrtx Employee Stock Purchase Plan Available For Issuance
EmployeeStockPurchasePlanAvailableForIssuance
99532
CY2015 hrtx Income Tax Reconciliation Net Operating Loss Not Benefited
IncomeTaxReconciliationNetOperatingLossNotBenefited
31935000
CY2014 hrtx Income Tax Reconciliation Net Operating Loss Not Benefited
IncomeTaxReconciliationNetOperatingLossNotBenefited
25085000
CY2013 hrtx Income Tax Reconciliation Net Operating Loss Not Benefited
IncomeTaxReconciliationNetOperatingLossNotBenefited
17983000
CY2015 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
1420000
CY2014 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
2038000
CY2013 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
1127000
CY2014 hrtx Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
58916000
CY2015 hrtx Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
128199000
CY2013 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
533000
CY2015 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2014 us-gaap Asset Impairment Charges
AssetImpairmentCharges
905000
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2015Q4 us-gaap Assets
Assets
137845000
CY2014Q4 us-gaap Assets
Assets
76682000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3300000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2549000
CY2015Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
36000
CY2014Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
886000
CY2015Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2965000
CY2014Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2012000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3914000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1775000
CY2015Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
61000
CY2014Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
105000
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1863000
CY2014Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
719000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5552000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4833000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-40000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
530617000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
378007000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10890000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8067000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14360000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14360000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8067000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10890000
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
624000
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
573000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
134751000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
73732000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
124075000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
57026000
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
0
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
55986000
CY2015 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2014 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2013 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2015 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2014 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2013 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2013 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0
CY2015 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
CY2014 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0
CY2013 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
40000
CY2014 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72675000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72287000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53506000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75180000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2505000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
388000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18781000
CY2015Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
131200000
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1000000
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3565477
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
23067406
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36106000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29227000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36106000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29227000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
361000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
292000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-97631000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76367000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55283000
CY2015 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2015 us-gaap Depreciation
Depreciation
734000
CY2014 us-gaap Depreciation
Depreciation
578000
CY2013 us-gaap Depreciation
Depreciation
333000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
734000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
578000
CY2015Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-20360000
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentration of Credit Risk</div></div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash, cash equivalents and short-term investments are financial instruments which potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits may be in excess of insured limits. We may also invest our excess cash in money market funds, corporate debt securities and commercial paper. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</div></div></div></div></div></div></div></div></div></div>
CY2013 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
291000
CY2014 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
309000
CY2015 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
328000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
113717000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
73272000
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
94465000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
59513000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1345000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
964000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11181000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7667000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6726000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5128000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
113717000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
73272000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
251000
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
181000
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
134000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2014 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2013 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2015Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-23014000
CY2015Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-22491000
CY2015Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-31060000
CY2014Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-17322000
CY2014Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-18791000
CY2014Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-18953000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
333000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.95
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.87
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.42
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.0034
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.0034
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.0034
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4828000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2731000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
63865000
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y109D
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
118000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-17000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5856000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6839000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8250000
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14797000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5694000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4512000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4222000
CY2014Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5300000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35742000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19728000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21941000
CY2014 us-gaap Interest Paid
InterestPaid
0
CY2013 us-gaap Interest Paid
InterestPaid
0
CY2015 us-gaap Interest Expense
InterestExpense
958000
CY2014Q2 us-gaap Interest Expense
InterestExpense
220000
CY2014Q3 us-gaap Interest Expense
InterestExpense
224000
CY2014Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-19495000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014Q4 us-gaap Interest Expense
InterestExpense
227000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-33181000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-25965000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-18796000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
894000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
551000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
513000
CY2015 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
352000
CY2014 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
329000
CY2013 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
300000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
751000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1285000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-426000
CY2015 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2097000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
165000
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2153000
CY2015 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1551000
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2876000
CY2013 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-36000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2443000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
419000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
54000
CY2015Q1 us-gaap Interest Expense
InterestExpense
232000
CY2015Q2 us-gaap Interest Expense
InterestExpense
237000
CY2015Q3 us-gaap Interest Expense
InterestExpense
242000
CY2015Q4 us-gaap Interest Expense
InterestExpense
247000
CY2014Q1 us-gaap Interest Expense
InterestExpense
216000
CY2014 us-gaap Interest Expense
InterestExpense
887000
CY2013 us-gaap Interest Expense
InterestExpense
828000
CY2015 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
333000
CY2014 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
314000
CY2013 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
295000
CY2015 us-gaap Interest Paid
InterestPaid
0
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
22000
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
61000
CY2015Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
65000
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
CY2014Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1502000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1381000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
967000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137845000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76682000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19735000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13620000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
137991000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62108000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61229000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56960000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1438000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1685000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78526000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60282000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40763000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-55283000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-76367000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-97591000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-20570000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-23107000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-22672000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-31242000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-17538000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-19011000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-19194000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-20624000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-666000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1806000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-826000
CY2015 us-gaap Operating Expenses
OperatingExpenses
96925000
CY2014 us-gaap Operating Expenses
OperatingExpenses
74561000
CY2013 us-gaap Operating Expenses
OperatingExpenses
54457000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-96925000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-74561000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-54457000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1070000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1067000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4154000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2931000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
130000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2015Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-17000
CY2014Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-905000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
292000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-919000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2015Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
143000
CY2014Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
165000
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
56115000
CY2014 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1086000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1438000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1685000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3585000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1057000
CY2011Q2 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4300000
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
257000
CY2014 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
91000
CY2013 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
34000
CY2015 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
128199000
CY2014 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
58916000
CY2013 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
57802000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
241000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9535000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3101000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2793000
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
600000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8601000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7653000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3049000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2820000
CY2015 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2015Q4 us-gaap Purchase Obligation
PurchaseObligation
3851000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14504000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16175000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14241000
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16263000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11628000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14279000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14731000
CY2014Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14195000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61183000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54833000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32516000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-412828000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315237000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
503343
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2237901
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1770597
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.72
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.01
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4256971
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.67
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13882000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3377000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
14360000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
8067000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
10890000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3880849
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2587392
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
71835
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1688135
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
862085
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
575178
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.45
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.88
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.42
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3181001
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2134505
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
46603000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14654000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8434988
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4323874
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6355681
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7918004
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.46
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.22
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.69
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.64
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8059481
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7841074
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6292296
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.38
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.69
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.22
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.34
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.15
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
19.24
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.16
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.08
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.40
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.95
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
8434988
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y255D
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1042343
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
537029
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
756593
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
34000
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
91000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
257000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57802000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2793000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3101000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9535000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
51818000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
68945000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
63062000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
118110000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
120000
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
120000
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
3192000
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.</div></div></div></div></div></div></div></div></div></div>
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
40445000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
32035000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33081000
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26569000
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16163000

Files In Submission

Name View Source Status
0001193125-16-469890-index-headers.html Edgar Link pending
0001193125-16-469890-index.html Edgar Link pending
0001193125-16-469890.txt Edgar Link pending
0001193125-16-469890-xbrl.zip Edgar Link pending
d126077d10k.htm Edgar Link pending
d126077dex1036.htm Edgar Link pending
d126077dex231.htm Edgar Link pending
d126077dex311.htm Edgar Link pending
d126077dex312.htm Edgar Link pending
d126077dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g126077g37j13.jpg Edgar Link pending
hrtx-20151231.xml Edgar Link completed
hrtx-20151231.xsd Edgar Link pending
hrtx-20151231_cal.xml Edgar Link unprocessable
hrtx-20151231_def.xml Edgar Link unprocessable
hrtx-20151231_lab.xml Edgar Link unprocessable
hrtx-20151231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending